A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors
To determine the recommended Phase 2 dose (RP2D) of LY3537982 monotherapy in patients with KRAS G12C-mutant advanced solid tumors
- IRB Number: 12289
- Research Study Identifier: TX11415
- Principal Investigator: Greg Durm, MD
Recruitment StatusEnrolling By Invitation
If you need help finding a study or have any questions, please contact us at email@example.com or by phone at (888) 264-0005.